New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
The phase 1/2a trial of BioNTech's BNT165e vaccine, involving nearly 180 participants, faces delays as global malaria control efforts struggle with funding and political uncertainties.